Welcome to our dedicated page for OS Therapies SEC filings (Ticker: OSTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OS Therapies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OS Therapies's regulatory disclosures and financial reporting.
OS Therapies registered 10,529,417 shares of common stock for resale by selling stockholders pursuant to a prospectus supplement dated March 31, 2026.
The registered shares consist of 2,622,774 shares issuable upon exercise of 2026 Warrants, 1,666,667 shares issuable upon exercise of Bridge Warrants and 6,239,976 shares issuable upon conversion of Bridge Notes. The company will receive no proceeds from resale by selling stockholders; it will receive proceeds only if outstanding warrants are exercised for cash.
OS Therapies Incorporated files its annual report as a clinical-stage biopharmaceutical company focused on Osteosarcoma and other solid tumors. Its lead candidate OST-HER2 showed improved two‑year overall survival versus historical controls and is being advanced toward potential FDA and European regulatory submissions.
The company has raised capital through PIPE, at-the-market, warrant inducement and bridge financings, but has incurred recurring losses, faces substantial doubt about its ability to continue as a going concern, and will need additional funding to complete development, obtain approvals and build commercialization capabilities.
OS Therapies Incorporated entered into a private placement on March 4, 2026, issuing 10.0% original issue discount unsecured convertible promissory notes and accompanying warrants to accredited investors for aggregate gross cash proceeds of $2,000,000.
The notes have an aggregate principal amount of $2,200,000, bear 4% annual interest, and mature on March 4, 2027, with both principal and accrued interest convertible into equity under mandatory and voluntary conversion features, including a 10‑day volume‑weighted price discount mechanism and anti‑dilution adjustments.
Investors also received warrants to purchase up to 1,666,667 common shares at an exercise price of $1.40 per share, based on an average prior trading price of $1.32, with 4.99% or 9.99% ownership caps and a 19.99% overall issuance limit unless stockholders approve more. Net proceeds are earmarked for clinical development, research and development, and general corporate purposes, and the company agreed to restrictive debt covenants, limitations on variable‑price financings, and to register the underlying shares for resale on a Form S‑3 or Form S‑1.
McKean-Dieser Avril Suzette reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Search Theodore F. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Ciccio John reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Acevedo Christopher P. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.
PETIT ROBERT reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.
Romness Paul A. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 1,000,000 shares. Following the reported transactions, holdings were 1,000,000 shares.
Jarry Olivier Roger reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.